Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026)
Quarterly Total Current Liabilities rose 27.65% to $56.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.0 million through Mar 2026, up 27.65% year-over-year, with the annual reading at $46.0 million for FY2025, 8.95% down from the prior year.
Oculis Holding AG's Total Current Liabilities history spans 6 years, with the latest figure at $56.0 million for Q1 2026.
- Total Current Liabilities came in at $56.0 million for Q1 2026, up from $46.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $56.0 million in Q1 2026 to a low of $12.5 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $32.0 million (2024), against an average of $33.8 million.
- Year-over-year, Total Current Liabilities surged 183.23% in 2022 and then decreased 8.95% in 2025.
- Oculis Holding AG's Total Current Liabilities stood at $12.5 million in 2022, then skyrocketed by 72.47% to $21.5 million in 2023, then soared by 134.65% to $50.5 million in 2024, then fell by 8.95% to $46.0 million in 2025, then increased by 21.83% to $56.0 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Total Current Liabilities are $56.0 million (Q1 2026), $46.0 million (Q4 2025), and $42.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 56.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.01 Mn |
| Dec 31, 2025 | 45.98 Mn |
| Sep 30, 2025 | 42.16 Mn |
| Jun 30, 2025 | 44.14 Mn |
| Mar 31, 2025 | 43.88 Mn |
| Dec 31, 2024 | 50.50 Mn |
| Sep 30, 2024 | 31.99 Mn |
| Jun 30, 2024 | 26.13 Mn |
| Mar 31, 2024 | 20.80 Mn |
| Dec 31, 2023 | 21.52 Mn |
| Sep 30, 2023 | 25.08 Mn |
| Jun 30, 2023 | 18.69 Mn |
| Dec 31, 2022 | 12.48 Mn |
| Dec 31, 2021 | 4.41 Mn |